{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:00:07Z","timestamp":1787169607904,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To report the initial experience of managing treatment-resistant and treatment-na\u00efve eyes with polypoidal choroidal vasculopathy (PCV) by using brolucizumab 6 mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This was a retrospective multicentric series of all consecutive eyes with PCV treated with brolucizumab. Treatment resistance was defined as taking at least six prior anti-VEGF injections over the past 1 year and showing persistent disease activity in the form of intra (IRF) or subretinal fluid (SRF) or both. All patients were treated on a\n                      <jats:italic toggle=\"yes\">pro re nata<\/jats:italic>\n                      (PRN) basis and followed up monthly. Retreatment was considered when either SRF or IRF were present at any time point during the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We included 21 eyes of 21 patients with PCV with a mean age of 65.1 \u00b1 9.9 years, of which 16 eyes (76%) were treatment-resistant. The mean follow-up period from receiving the first brolucizumab was 27.3 \u00b1 3.3 weeks. Of the 21 eyes, seven eyes (33%) received three injections during follow-up, 13 eyes (62%) received two injections, and one eye received one injection. The mean injection-free interval was 12 \u00b1 1.2 weeks. The median pretreatment vision was 0.6 logMAR (IQR = 0.47\u20131 logMAR) and improved to 0.3 logMAR (IQR = 0.25\u20130.6 logMAR), whereas the mean macular thickness improved from 443 \u00b1 60 mm at baseline to 289 \u00b1 25 mm (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) at the last follow-up period. None of the eyes experienced any intraocular inflammation across 48 injection sessions\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Brolucizumab is safe and effective in controlling PCV disease in both treatment-resistant and treatment-na\u00efve eyes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2513_21","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T07:53:23Z","timestamp":1648454003000},"page":"1295-1299","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Initial experience in treating polypoidal choroidal vasculopathy with brolucizumab in Indian eyes \u2013 A multicenter retrospective study"],"prefix":"10.4103","volume":"70","author":[{"given":"Debdulal","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Vitreo-Retina Services, Disha Eye Hospitals, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Maiti","sequence":"additional","affiliation":[{"name":"Netralayam Super Speciality Eye Care Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Vitreo-Retina Services, Consultant Vitreoretinal Surgeon, Future Vision Eye Care and Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumen","family":"Mondal","sequence":"additional","affiliation":[{"name":"Vitreo-Retina Services, Disha Eye Hospitals, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnendu","family":"Nandi","sequence":"additional","affiliation":[{"name":"Netralayam Super Speciality Eye Care Centre, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Retina Institute of Bengal, Siliguri, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"B1-20240828","article-title":"Evolving treatment paradigms for PCV","author":"Fenner","year":"2021","journal-title":"Eye (Lond)"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4103\/ijo.IJO_1136_17","article-title":"Polypoidal choroidal vasculopathy: Pearls in diagnosis and management","volume":"66","author":"Anantharaman","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: Definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ajo.2012.09.020","article-title":"Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy","volume":"155","author":"Kang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: A randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-Six-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"B9-20240828","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK","author":"Ogura","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","article-title":"Short-term outcomes of intravitreal brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy","volume":"11","author":"Matsumoto","year":"2021","journal-title":"Sci Rep"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: Post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ajo.2014.08.025","article-title":"Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy","volume":"158","author":"Salvo","year":"2014","journal-title":"Am J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2513_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:09:59Z","timestamp":1787166599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2513_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2513_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"2021-09-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}